Researchers calibrated the CORE model with baseline characteristics from LEAD-1 and projected outcomes, including survival rates, cardiovascular, ophthalmic, and renal events incidence, and healthcare expenditures over 10-, 20-, and 30-year intervals (16)(17)
The percentage of patients who discontinued due to ineffective therapy was 5.4% in the liraglutide injection 1.8 mg + metformin treatment group, 3.3% in the liraglutide injection 1.2 mg + metformin treatment group, 23.8% in the placebo + metformin treatment group, and 3.7% in the glimepiride + metformin treated group
References: Anderson SD, Anderson KV (2023): Drugs for Heart Failure
Are weight loss drugs covered by insurance
Prolonged hemodialysis may be considered if clinically appropriate
Labs are not required to start or continue treatment, but Fridays coordinates optional blood work through Quest Diagnostics for patients who want or need it